Development of HeartPrint Bioink

点击翻译按钮获取中文摘要

3D bioprinting enables to generation of human tissue models for screening potential drug targets in a more relevant fashion compared to animal models. Animal models fail to predict the toxicity of potential drug targets on cardiovascular system, including the heart. 40% of drugs that enter clinical trials fail as a result of unexpected cardiotoxicity. Thus, a huge market exists for a bioink capable of printing human cardiac tissues that can be used to screen potential drugs for this issue. This project will upon our team's expertise in producing TissuePrint and BrainPrint to perform the research and development necessary to generate such a bioink, which we have termed "HeartPrint". HeartPrint bioink fills this important market gap and this project will further enable research and development here in Canada. This Lab to Market project will be conducted by Milena Perez - an award winning biomedical engineer at the University of Victoria - who has already published three well received, peer reviewed journal articles about using 3D bioprinting to produce stem cell-derived tissues. This project will be conducted under the guidance of Dr. Willerth - an internationally recognized expert in 3D printing and tissue engineering.